Molecular Mechanism of Matrix GLA Protein (MGP)

基质 GLA 蛋白 (MGP) 的分子机制

• 批准号: 7367839
• 负责人: Kristina I Bostrom
• 金额: $ 37.5万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-24 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7367839
• 关键词: Activin Receptor; Affect; Amino Acids; Arterial Fatty Streak; Arteries; Atherosclerosis; BMP2 gene; Blood Vessels; Bone Growth; Bone Matrix; Bone Morphogenetic Proteins; C-terminal; Calcified; Cells; Cessation of life; Clinical; Coronary heart disease; Data; Development; Dissection; Endothelial Cells; Endothelium; Feedback; Gene Expression; Genes; Grant; Heart Diseases; Heart Valves; Human; Immunoprecipitation; Intervention; Knockout Mice; Laboratories; Link; Low Density Lipoprotein Receptor; Medial; Mesenchymal; Molecular; Morbidity - disease rate; Mus; Peripheral; Process; Protein Deficiency; Proteins; Proteomics; Pulmonary artery structure; Regulation; Reporter Genes; Risk; Role; Rupture; Sclerosis; Signal Pathway; Signal Transduction; Smooth Muscle Myocytes; Syndrome; Testing; Transforming Growth Factors; Transgenic Mice; Tunica Media; Vascular Diseases; Vascular Endothelial Growth Factors; Vascular calcification; Vitamin K; activin receptor-like kinase 1; artery stenosis; bone; bone morphogenetic protein 2; bone morphogenetic protein 4; bone morphogenetic protein receptors; calcification; calcification inhibitor; carboxylation; coronary artery calcification; design; improved; inhibitor/antagonist; insight; low density lipoprotein inhibitor; matrix Gla protein; mortality; prevent; protein function; protein protein interaction; receptor; systolic hypertension

Calcification is ubiquitous in vascular disease, and contributes significantly to morbidity and mortality. Matrix GLA protein (MGP) is an alleged calcification inhibitor that is up-regulated in atherosclerotic lesions. Deletion of the MGP gene results in arterial calcification and in morphological abnormalities in mice and humans. MGP is a secreted protein that is modified by vitamin K-dependent g-carboxylation. When isolated from bone, it is processed and lacks seven C-terminal amino acids. The mechanism of MGP is poorly understood. However, our experimental data points to a role in transforming growth factor-fi (TGF-fi) and bone morphogenetic protein (BMP) signaling. The data suggest a potential link between BMP and TGF-li in that BMP2 and BMP-4 induce expression of the TGF-R, receptor Activin-like Kinase receptor 1 (ALK1). Signaling through ALK1 induces MGP, which provides negative feedback regulation for BMP. Interactions between MGP and specific receptors were also observed. Three hypotheses will be tested in this grant. The first hypothesis is that MGP regulates TGF-fi and BMP signaling at the receptor level, resulting in altered SMAD signaling and gene expression. We will characterize activation of SMAD signaling and relevant reporter genes induced by TGF-li1, BMP-2 and BMP-4 in presence of MGP, and identify the TGF-li / BMP receptors that are regulated by MGP. The second hypothesis is that MGP participates in specific protein-protein interactions that may be altered by C-terminal processing. We will characterize the interactions, which include the TGF-ft receptors, using specific immunoprecipitations in combination with a general proteomic approach. The third hypothesis is that MGP functions as a BMP inhibitor in developing arteries and in atherosclerotic lesions. We will generate a transgenic mouse for targeted, conditional expression of the BMP-inhibitor Noggin. Noggin expression will be induced in MGP null mice in attempt to replace MGP and abolish calcification. The effect of Noggin will also be determined in atherosclerotic lesions in LDL-receptor null mice. Our results will add insight to calcification of vessels and heart valves, a common problem in heart disease. In addition, it may provide information on how to design new treatments for unwanted calcification.

钙化在血管疾病中普遍存在，并与发病率和死亡率密切相关。矩阵 GLA蛋白(MGP)是一种钙化抑制因子，在动脉粥样硬化病变中表达上调。删除 MGP基因的突变会导致动脉钙化，并导致小鼠和人类的形态异常。 MGP是一种分泌型蛋白质，通过维生素K依赖的g-羧化修饰。当被隔离时 骨骼，它是经过加工的，缺乏七个C-末端氨基酸。 MGP的发病机制目前知之甚少。然而，我们的实验数据表明， 转化生长因子-FI和骨形态发生蛋白信号转导。这些数据表明， BMP-1与BMP-1在BMP-2和BMP-4诱导转化生长因子受体表达中的潜在联系 激活素样激酶受体1(ALK1)。通过ALK1的信号诱导MGP，MGP提供负值 骨形态发生蛋白的反馈调节。MGP与特异性受体的相互作用也被观察到。 三个假设将在这项拨款中得到检验。第一种假设是MGP调节转化生长因子-FI和骨形态发生蛋白 在受体水平上的信号，导致SMAD信号和基因表达的改变。我们将描述 转化生长因子-1、骨形态发生蛋白-2和骨形态发生蛋白-4诱导的SMAD信号及相关报告基因的激活 MGP的存在，并鉴定受MGP调控的转化生长因子-1/骨形态发生蛋白受体。第二 假设MGP参与特定的蛋白质-蛋白质相互作用，这种相互作用可能被C-末端改变 正在处理。我们将使用特定的基因来描述相互作用，包括转化生长因子-ft受体。 免疫沉淀结合一般蛋白质组学方法。第三个假设是MGP 在发育中的动脉和动脉粥样硬化病变中作为BMP抑制物发挥作用。我们将生成一个 靶向、有条件表达BMP抑制物Noggin的转基因小鼠。Noggin表达式将为 在MGP基因缺失的小鼠中诱导，试图取代MGP并消除钙化。诺金的影响也将 在低密度脂蛋白受体缺失小鼠的动脉粥样硬化病变中被确定。 我们的结果将增加对血管和心脏瓣膜钙化的洞察，这是心脏病中的一个常见问题。 此外，它还可能提供有关如何为不想要的钙化设计新的治疗方法的信息。